Dynavax Technologies is a California-based company in the biotechnology industry with a focus on developing novel vaccines. Its first commercial product was a Hepatitis B vaccine called HEPLISAV-B.It develops its medical solutions using Toll-like Receptor (TLR) technology.
The company entered into a partnership with Clover Biopharmaceuticals, a Chinese biotechnology company, to develop a vaccine candidate for COVID-19. The company's roll in the partnership includes technical expertise as well as CpG 1018, an adjuvant that is used in creating vaccines such as the company's own HEPLISAV-B.
Dynavax Technologies also partnered with Sinovac to combine its adjuvant CpG 1018 with Sinovac's chemically inactivated vaccine candidate for COVID-19.
President and COO
Covid 19 vaccine to be worked on by Dynavax, UQ and CEPI.
March 3, 2020
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
Dynavax Technologies Corporation
March 24, 2020
Documentaries, videos and podcasts
The Next Big Thing In Biotech: Dynavax
November 9, 2012
- CompanyA company, abbreviated as "Co." within a company name, is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.
- BiotechnologyBiotechnology in a broad sense includes the use of living systems and organisms, as well as their parts for the development or production of products.
- COVID-19COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the World Health Organization.